ERBB2 and breast neoplasm: This led to the development of trastuzumab, a specific anti-HER2 humanized recombinant monoclonal antibody (mAb), which showed considerable clinical utility in patients with HER2-overexpressing breast tumors in both metastatic [6]–[10] and adjuvant [11]–[13] settings.